iPPI-DB

Inhibitors of Protein-Protein Interaction Database

Compound 2264

Identifiers

  • Canonical SMILES: 
    CN(C)C(=O)c1cccc(c1)-c1cn(CCC=C)c(=O)c2[nH]ccc12
  • IUPAC name: 
    3-[6-(but-3-en-1-yl)-7-oxo-1H,6H,7H-pyrrolo[2,3-c]pyridin-4-yl]-N,N-dimethylbenzamide
  • InChi: 
    InChI=1S/C20H21N3O2/c1-4-5-11-23-13-17(16-9-10-21-18(16)20(23)25)14-7-6-8-15(12-14)19(24)22(2)3/h4,6-10,12-13,21H,1,5,11H2,2-3H3
  • InChiKey: 
    VNCNIMOILJQAGJ-UHFFFAOYSA-N

External links


119081691
CHEMBL4436158
67C

External search

Bibliography (1)

Publication Name
Crawford Terry D., Tsui Vickie, Flynn E. Megan, Wang Shumei, Taylor Alexander M., Côté Alexandre, Audia James E., Beresini Maureen H., Burdick Daniel J., Cummings Richard, Dakin Les A., Duplessis Martin, Good Andrew C., Hewitt Michael C., Huang Hon-Ren, Jayaram Hariharan, Kiefer James R., Jiang Ying, Murray Jeremy, Nasveschuk Christopher G., Pardo Eneida, Poy Florence, Romero F. Anthony, Tang Yong, Wang Jian, Xu Zhaowu, Zawadzke Laura E., Zhu Xiaoyu, Albrecht Brian K., Magnuson Steven R., Bellon Steve, Cochran Andrea G.. . Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains Journal of Medicinal Chemistry. Compound 5

Pharmacological data

Biochemical tests Cellular tests PK tests Cytotoxicity tests
5 0 0 0

Targets

PPI family Best activity Diseases MMoA
Bromodomain / Histone 7.34 cancer Inhibition
Physicochemical filters
Descriptor Lipinski's RO5 Veber Pfizer's 3/75
Compliance
MW 335.16 g/mol
HBA 5
HBD 1
HBA + HBD 6
AlogP 2.30
TPSA 56.41
RB 5
Radar chart
PCA : iPPI-DB chemical space
PCA : Correlation circle
Efficiencies: iPPI-DB biplot LE versus LLE
Summary
Bibliographic ressources Biochemical tests Cellular tests PK tests Cytotoxicity tests
1 5 0 0 0
Pharmacological data
Bibliography Name Target Competition Assay type Assay name Cell line Activity type Activity
10.1021/acs.jmedchem.6b00264 Compound 5 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET BRD4(1) pIC50 (half maximal inhibitory concentration, -log10) 5.60
10.1021/acs.jmedchem.6b00264 Compound 5 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET BRD4(2) pIC50 (half maximal inhibitory concentration, -log10) 5.26
10.1021/acs.jmedchem.6b00264 Compound 5 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET BRD9 pIC50 (half maximal inhibitory concentration, -log10) 5.85
10.1021/acs.jmedchem.6b00264 Compound 5 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET TAF1(1) pIC50 (half maximal inhibitory concentration, -log10) 7.34
10.1021/acs.jmedchem.6b00264 Compound 5 BRD4
O60885 		H4
P62805 		Biochemical assay Time-Resolved FRET CECR2 pIC50 (half maximal inhibitory concentration, -log10) 5.32
Ta Structure Name Drugbank ID
0.5091 Ozenoxacin DB12924
0.4943 2-amino-5-[3-(1-ethyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]-N,N-dimethylbenzamide DB08583
0.4884 N-(2-hydroxy-1,1-dimethylethyl)-1-methyl-3-(1H-pyrrolo[2,3-b]pyridin-2-yl)-1H-indole-5-carboxamide DB06834
0.4848 Dactolisib DB11651
0.4756 5-[3-(2-METHOXYPHENYL)-1H-PYRROLO[2,3-B]PYRIDIN-5-YL]-N,N-DIMETHYLPYRIDINE-3-CARBOXAMIDE DB08350
0.4740 LY-3023414 DB12167
0.4725 4-(2-chlorophenyl)-8-(2-hydroxyethyl)-6-methylpyrrolo[3,4-e]indole-1,3(2H,6H)-dione DB07257
0.4706 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine DB08398
0.4671 3-(2-aminoquinazolin-6-yl)-4-methyl-1-[3-(trifluoromethyl)phenyl]pyridin-2(1H)-one DB07528
0.4658 3-(5-{[4-(AMINOMETHYL)PIPERIDIN-1-YL]METHYL}-1H-INDOL-2-YL)QUINOLIN-2(1H)-ONE DB07025
0.4615 1-{3-oxo-3-[(2S)-2-(pyrrolidin-1-ylcarbonyl)pyrrolidin-1-yl]propyl}-3-phenylquinoxalin-2(1H)-one DB08738
0.4589 Rosoxacin DB00817
0.4580 Amrinone DB01427
0.4568 GSK-364735 DB13119
0.4561 3-(9-HYDROXY-1,3-DIOXO-4-PHENYL-2,3-DIHYDROPYRROLO[3,4-C]CARBAZOL-6(1H)-YL)PROPANOIC ACID DB07265